Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
RESEARCH TOOLSreports
Holding BMRN?
Track your performance easily
BMRN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$60.63 - $94.85
Previous CloseN/A
Volume465.01K
Average Volume (3M)1.53M
Market Cap
$11.76B
Enterprise Value$13.54B
Total Cash (Recent Filing)$789.68M
Total Debt (Recent Filing)$660.76M
Price to Earnings (P/E)37.2
Beta0.55
Next Earnings
Feb 20, 2025EPS Estimate
0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.66
Shares Outstanding190,583,020
10 Day Avg. Volume2,192,707
30 Day Avg. Volume1,534,299
Standard Deviation0.09
R-Squared0.03
Alpha-0.00310
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.27
Price to Cash Flow (P/CF)13.30
P/FCF Ratio14.70
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue4.92
Enterprise Value/Gross Profit7.11
Enterprise Value/Ebitda26.84
Forecast
1Y Price Target
$100.91Price Target Upside59.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
BioMarin Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Market PositionVoxzogo has a high compliance rate of 95%, a ~5-year lead over any potential competitor, a broad US label from birth, a long-term safety database, and growing evidence of benefit beyond growth.
Pipeline DevelopmentBMN 333 is highlighted as the company's most important pipeline asset, with management aiming to significantly improve efficacy compared to Voxzogo.
Strategic GrowthCEO Alexander Hardy communicated a strategy to bring shareholder value by strengthening the company's finances through increasing top-line growth and expanding their commercial enzyme replacement therapy business globally.
Bears Say
Legal ChallengesA lawsuit filed against ASND claims infringement of their long-acting patent, but there's a bearish outlook on the strength and validity of BMRN's intellectual property.
Market PerformanceBMRN shares are near a 10-year low after the company fumbled on several programs that have either failed to reach the market or had their market opportunity reigned in and there is little confidence within the investment community that Voxzogo can retain leadership in the achondroplasia market in the face of two potential competitors.
Product Launch IssuesThe disappointing launch of Roctavian so far is mainly due to the lack of an established reimbursement environment.
---
Ownership Overview
0.95% Insiders
36.73% Mutual Funds
0.42% Other Institutional Investors
39.39% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $60.63 and its highest was $94.85 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
BioMarin Pharmaceutical’s market cap is $11.76B.
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Feb 20, 2025 which is in 18 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Oct 29, 2024. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.531 by $0.019.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is 0.53.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 190,583,020 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $0.55 in its last earnings report, beating expectations of $0.531. Following the earnings report the stock price went down -4.62%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Among the largest hedge funds holding BioMarin Pharmaceutical’s share is PRIMECAP Management Co. It holds BioMarin Pharmaceutical’s shares valued at 1B.
---
BioMarin Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$100.91 (59.26% Upside)
$100.91 (59.26% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $350.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days >0.1%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.12%
12-Months-Change
Fundamentals
Return on Equity
5.95%
Trailing 12-Months
Asset Growth
1.38%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
---
BMRN Company Deck
---
BMRN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
BioMarin's third quarter performance showed strong revenue growth and profitability expansion, supported by successful commercial execution and strategic initiatives. However, challenges in Roctavian revenue and increased competition in the achondroplasia market introduce some risks.Read More>---
BMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
---
BMRN Stock 12 Month Forecast
Average Price Target
$100.91
▲(59.26% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Regeneron
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering BMRN
1 Year
1 Year Success Rate
21/46 ratings generated profit
1 Year Average Return
-2.55%
assigned a buy rating 19 days ago
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 45.65% of your transactions generating a profit, with an average return of -2.55% per trade.
---